Boston 2014: ClinicalThought

November 15-19, 2014; Boston, Massachusetts
In these highlights from the ClinicalThought program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of lupus, psoriatic arthritis, and spondyloarthritis.
Vinod Chandran, MBBS, MD, DM, PhD
Atul Deodhar, MD
Daniel J. Wallace, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: March 19, 2015 Expiration: March 18, 2016

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the importance of patient-reported outcomes and potential implications of ongoing clinical trials for the care of patients with systemic lupus erythematosus
  • Describe the risks and benefits of treatments available and under investigation for the treatment of psoriatic arthritis
  • Discuss with patients and colleagues the potential role of novel treatment options under investigation for the treatment of ankylosing spondylitis

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Vinod Chandran, MBBS, MD, DM, PhD

Assistant Professor
Consultant Rheumatologist
Division of Rheumatology
Department of Medicine
University of Toronto
University Health Network
Toronto, Canada

Vinod Chandran, MBBS, MD, DM, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, Novartis, Pfizer, and UCB and funds for research support from AbbVie and Eli Lilly and Company.
Atul Deodhar, MD
Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon
Atul Deodhar, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Janssen, Novartis, and UCB.
Daniel J. Wallace, MD

Clinical Professor
Department of Medicine
Cedars Sinai/UCLA
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Daniel J. Wallace, MD, has disclosed that he has received consulting fees from GlaxoSmithKline and UCB and funds for research support from GlaxoSmithKline.

Staff

Andrew D. Bowser, ELS, CHCP

Director, Educational Strategy and Outcomes

Andrew D. Bowser, ELS, CCMEP, has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for rheumatologists and other healthcare providers who manage patients with rheumatic diseases.

Goal

The goal of this activity is to educate rheumatology specialists and other clinicians on recent research developments that have clinical implications for the management of patients with rheumatic diseases.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 19, 2015, through March 18, 2016:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides on managing psoriatic conditions to improve quality of life, including treatment considerations and comorbidity screening

Lakshi M. Aldredge, MSN, ANP-BC, DCNP Released: August 20, 2019

CE-certified interactive video for nurses with expert discussion on assessing QoL, managing comorbidities, and treating psoriasis or psoriatic arthritis.

Lakshi M. Aldredge, MSN, ANP-BC, DCNP Registered Nurses: 1.3 Nursing contact hours Registered Nurse Practitioners: 1.3 Nursing contact hours Released: August 20, 2019 Expiration: August 19, 2020

Point-of-care PDF on therapies for psoriasis and psoriatic arthritis: Review dose, monitoring, adverse events for topicals, oral systemics, biologics.

Lakshi M. Aldredge, MSN, ANP-BC, DCNP Released: August 2, 2019

In this downloadable slideset, Anca D. Askanase, MD, MPH; David R. Fernandez, MD, PhD; and Jane E. Salmon, MD, review best practices in SLE diagnosis and management and discuss emerging targeted therapeutics, with a focus on women of color.

Released: March 13, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?